Sipra review

Sipra gives more plan and refund detail than a single starting-price banner, but its longer plans require real upfront commitment. Compare the amount charged, the quarter-based exit calculation and your state’s care availability before treating a lower monthly equivalent as a saving.

Sipra LLC is described in its consent as a Wyoming technology platform. Clinical services are attributed to MDI Medical Group PC and affiliated state professional corporations, using the MD Integrations name. The separate medical privacy notice identifies the clinical provider as the covered entity and distinguishes it from Sipra’s administrative role. That separation is useful when asking who holds a medical record or handles a care complaint. It does not independently verify a clinician’s credentials or tell every applicant their exact treating practice. Ask for the legal practice and prescriber assigned to your state. The consent describes fulfillment through Epiq Scripts LLC, a pharmacy routed through the VSDH One platform, or a retail pharmacy for branded products. It also recognizes pharmacy choice. A routing service is not necessarily the dispensing pharmacy, so obtain the actual name and label contact details for your order. Confirm whether a different pharmacy changes the bundled price or refill arrangements.

The weight-care page describes an online visit, physician review, approval, pharmacy preparation and ongoing check-ins. The public offer includes visits, follow-up messaging, medication when approved and shipping. That is a useful starting description, but applicants should establish how clinical questions are handled between fills and when a live appointment is available. Completing the questionnaire does not ensure a prescription. The medical team may change treatment, request tests or direct a patient to in-person care. Sipra’s terms make lab work and add-on therapies separate charges. Ask which are required for your proposed plan, rather than assuming a medication bundle covers every possible expense. Sipra uses all-fifty-state marketing, while its documents qualify availability by location and licensure. Its telehealth consent still marks multiple state addenda as awaiting attorney review, including California, Connecticut, New Jersey, New York, Texas and Florida. This is a meaningful documentation gap, not proof that care is either available or prohibited in those states. Confirm current eligibility and receive the applicable consent before paying. A shipping promise cannot settle where a clinician can treat you. The actual state where a visit takes place matters, including when traveling.

For standard compounded injections, the pricing table lists semaglutide at $199 every four weeks, or $477 for three months, $774 for six and $1,188 for twelve. Tirzepatide is $299 every four weeks, or $747, $1,314 and $2,388 for those longer lengths. Four weeks is twenty-eight days, so that short-plan cadence is not the same as twelve calendar-month payments a year. The weight-loss card separately advertises semaglutide from $149 per month. Do not combine that card with the standard injection table or assume it is a universal quote. Microdose and oral ODT prices are separate products. Multi-month plans are paid upfront and longer plans ship quarterly; a monthly equivalent is not a monthly installment. Sipra says physician approval precedes the charge. Save the selected checkout total, recurring authorization and refill schedule, including any separate laboratory charges. The refund policy recommends canceling at least thirteen calendar days before the paid period ends to avoid preparation of the next prescription. Once an order reaches the pharmacy, cancellation cannot necessarily stop it. Use the account or support cancellation channel and obtain confirmation. Approval, preparation, shipment and the end of a paid period are separate milestones, so ask which has occurred before estimating money back.

Sipra explicitly lists compounded semaglutide and tirzepatide injections and oral ODTs. The ingredient and route labels make those offers distinguishable, but do not establish that an oral compound is clinically interchangeable with an approved tablet or an injection. Its consent states that compounds are not FDA-approved or generic versions of branded GLP-1 medicines. Ask for the preparation-specific ingredient, concentration, quantity, dosing instructions and pharmacy label. Separate microdose plans should not be compared as though they buy the same prescribed treatment as standard injections. Promotional outcomes or dose convenience are not evidence that a particular compounded formulation reproduces another medicine’s clinical results. The cancellation decision also depends on plan length. Under the controlling terms, one- and three-month plans become nonrefundable after physician approval. Six- and twelve-month plans can refund the portion beyond started or pharmacy-sent quarters, but retained months are repriced at the closest shorter plan: three months at the quarterly rate and six or nine at the six-month rate. The original discount is therefore not retained proportionally. The promise applies once per medication and to the purchased plan, not renewals; physician discontinuation has a separate pro-rata rule for medication not yet sent to the pharmacy. Ask for a worked exit calculation before choosing an annual plan. A reader uncertain about tolerability or continuing treatment should weigh that potential exit cost alongside the upfront amount. A longer commitment is attractive only if its cash requirement and restrictions fit the reader’s actual circumstances. For a shipment concern, contact the dispensing pharmacy for product-specific storage and handling advice rather than relying on a general expedited-shipping banner.